Search Results 1-10 of 16478 for ������������KA���:ZA31���24������ ���������������������������������
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
This study is being conducted to examine survival, safety, and the magnitude of the immune response induced following administration of DN24-02 in subjects with ...
Researchers found that the ratio of 25(OH)D-to-24,25(OH)2D is necessary to estimate the calculation of vitamin D 24-hydroxylase enzyme activity to confirm ...
... KA. Intraoperative Radiation Therapy (IORT) in ... 24-00665R1) The Lancet Oncology. 2024. Routman DM ... 2024 Mar 12; 24(1):332. View PubMed; Zhang L ...
24. Risk Reduction Strategies ... 24. Safe and Positive Options for Bystander Intervention ...
National/Regional 3/26/2018 1/24/2018. Pregnancy ... Presentation - National/Regional n/a 7/24/2017 ... Robinson KA, Kriegshauser JS, Dahiya N, Young SW, Czaplicki ...
Young KA, Rodeheffer RJ, Bird JG, Miranda WR ... 2024 Dec 17; 13 (24):e038965 Epub 2024 Dec 14 ... 2022 Oct; 35 (10):1055-1063 Epub 2022 June 24. View ...
Rochester, Minnesota: 24-002915. NCT ID: NCT06940297. Sponsor Protocol Number: MC240801. About this study. This phase II trial tests how well giving dasatinib ...
... 24 visit. Males (as assigned at birth) must fulfill the following criteria ... difficile-related diarrhea within 8 weeks after receiving CP101 or placebo in Part ...
Serum creatinine must be stable (with no increases ≥ 20%) for a minimum of 24 weeks post-renal crisis at the time of the screening visit. Cardiac ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.